Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine

Clinical Neuropharmacology

Volumn 25, Issue 2, 2002, Pages 122-123

  Jhee, Stanford S ^a   Shiovitz, Thomas ^a   Hartman, Richard D ^a   Messina, John ^a   Anand, Ravi ^a   Sramek, John ^a   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CHOLINESTERASE INHIBITOR; GLYCOPYRRONIUM BROMIDE; ONDANSETRON; RIVASTIGMINE; TRIHEXYPHENIDYL; TRIMETHOBENZAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; AREA POSTREMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEADACHE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIEMETICS; CARBAMATES; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PHENYLCARBAMATES; PILOT PROJECTS; PROSPECTIVE STUDIES; VOMITING;

EID: 0036117644     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200203000-00013     Document Type: Letter

References (3)

1. Muscarinic cholinergic receptors in area postrema and brainstem areas regulating emesis
2. Trihexyphenidyl in posthemorrhagic dystonia: Motor and language effects
3. Agents affecting gastrointestinal water flux and motility